128 related articles for article (PubMed ID: 8155393)
1. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.
Treskes M; Boven E; van de Loosdrecht AA; Wijffels JF; Cloos J; Peters GJ; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 1994; 30A(2):183-7. PubMed ID: 8155393
[TBL] [Abstract][Full Text] [Related]
2. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Treskes M; Boven E; Holwerda U; Pinedo HM; van der Vijgh WJ
Cancer Res; 1992 Apr; 52(8):2257-60. PubMed ID: 1313740
[TBL] [Abstract][Full Text] [Related]
3. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
[TBL] [Abstract][Full Text] [Related]
4. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
Treskes M; van der Vijgh WJ
Cancer Chemother Pharmacol; 1993; 33(2):93-106. PubMed ID: 8261581
[TBL] [Abstract][Full Text] [Related]
5. Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts.
Treskes M; Nijtmans L; Fichtinger-Schepman AM; van der Vijgh WJ
Anticancer Res; 1992; 12(6B):2261-5. PubMed ID: 1338281
[TBL] [Abstract][Full Text] [Related]
6. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.
Treskes M; Holwerda U; Klein I; Pinedo HM; van der Vijgh WJ
Biochem Pharmacol; 1991 Nov; 42(11):2125-30. PubMed ID: 1659819
[TBL] [Abstract][Full Text] [Related]
7. Protection against late effects of radiation by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
Grdina DJ; Carnes BA; Grahn D; Sigdestad CP
Cancer Res; 1991 Aug; 51(16):4125-30. PubMed ID: 1651155
[TBL] [Abstract][Full Text] [Related]
8. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
9. The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)- ethylphosphorothioic acid (WR 2721).
Millar JL; McElwain TJ; Clutterbuck RD; Wist EA
Am J Clin Oncol; 1982 Jun; 5(3):321-8. PubMed ID: 6282111
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of carboplatin.
van der Vijgh WJ
Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899
[TBL] [Abstract][Full Text] [Related]
11. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
Br J Cancer; 1997; 75(10):1439-46. PubMed ID: 9166935
[TBL] [Abstract][Full Text] [Related]
12. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
van der Vijgh WJ; Korst AE
Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
[TBL] [Abstract][Full Text] [Related]
13. WR2721 protection of bone marrow in 131I-labeled antibody therapy.
Badger CC; Rasey J; Nourigat C; Fisher DR; Hui TE; Wu ZM; Bernstein ID
Radiat Res; 1991 Dec; 128(3):320-4. PubMed ID: 1660165
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of recombinant human leukemia inhibitory factor against thrombocytopenia in carboplatin-treated mice.
Akiyama Y; Kikuchi Y; Matsuzaki J; Kajimura N; Ohue C; Yamaguchi K
Jpn J Cancer Res; 1997 Jun; 88(6):584-9. PubMed ID: 9263536
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of antitumor activities of carboplatin and camptothecin by interleukin-1 alpha against human ovarian carcinoma in vivo.
Wang Z; Benchekroun MN; Sinha BK
Anticancer Res; 1994; 14(5A):1723-6. PubMed ID: 7847805
[TBL] [Abstract][Full Text] [Related]
16. Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models.
Lin X; Zhang Q; Rice JR; Stewart DR; Nowotnik DP; Howell SB
Eur J Cancer; 2004 Jan; 40(2):291-7. PubMed ID: 14728945
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
Betticher DC; Anderson H; Ranson M; Meely K; Oster W; Thatcher N
Br J Cancer; 1995 Dec; 72(6):1551-5. PubMed ID: 8519676
[TBL] [Abstract][Full Text] [Related]
18. Intraoral manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) radioprotective gene therapy decreases ionizing irradiation-induced murine mucosal cell cycling and apoptosis.
Epperly MW; Carpenter M; Agarwal A; Mitra P; Nie S; Greenberger JS
In Vivo; 2004; 18(4):401-10. PubMed ID: 15369176
[TBL] [Abstract][Full Text] [Related]
19. Influence of WR2721 on DNA cross-linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo.
DeNeve WJ; Everett CK; Suminski JE; Valeriote FA
Cancer Res; 1988 Nov; 48(21):6002-5. PubMed ID: 2844397
[TBL] [Abstract][Full Text] [Related]
20. Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth.
Das B; Antoon R; Tsuchida R; Lotfi S; Morozova O; Farhat W; Malkin D; Koren G; Yeger H; Baruchel S
Neoplasia; 2008 Oct; 10(10):1105-19. PubMed ID: 18813359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
